Limits...
Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy

View Article: PubMed Central - PubMed

ABSTRACT

Background. The IL-33/ST2 axis is involved in humoral immune responses. Method. The concentrations of sera IL-33 and sST2 in 74 patients and 34 healthy controls (HC) were measured by ELISA. Clinical and laboratory data were examined. The potential association between sera IL-33 and sST2 and the clinical parameters in IgAN patients were analyzed. Results. No difference was discovered in IL-33 concentrations between IgAN patients and HCs; however, the sST2 were significantly higher in each stage of IgAN progression than in the HC. The concentration of sST2 was positively correlated with IL-33 levels in IgAN patients. Higher levels of sera IL-2, IL-4, IL-10, IL-17A, and IFN-γ were detected in patients compared to the HC. The concentration of serum sST2 was positively correlated with the levels of IL-10 in IgAN patients. Furthermore, serum sST2 was negatively correlated with the values of eGFR and serum calcium. Serum sST2 was positively correlated with 24-hour urinary protein, serum phosphorus, and serum IgA; however, serum IL-33 was not associated with these. Following treatment, serum sST2 was significantly decreased, while sera IL-4 and IL-10 were significantly increased. Conclusions. Increased sST2 and IL-10 but not IL-33 may be involved in the pathogenic process of IgAN.

No MeSH data available.


Analysis of sera IL-33 and sST2 in IgAN patients and HC. The levels of sera sST2 and IL-33 in IgAN patients and HCs were tested by ELISA. Data are expressed as the mean values of individual participants from two separate experiments; horizontal lines represent the median values of different groups. (a) Analysis of serum IL-33 levels revealed no obvious differences among different stage IgAN patients and healthy controls (HC) (all p > 0.05). No significant difference in the levels of serum IL-33 was found among each stage of IgAN patients. (b) Serum sST2 levels were significantly higher in each stage of IgAN patients than in HC and furthermore tended to increase in parallel with the severity of the histopathological classification of IgAN (r = 0.443, p < 0.001).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC5120178&req=5

fig1: Analysis of sera IL-33 and sST2 in IgAN patients and HC. The levels of sera sST2 and IL-33 in IgAN patients and HCs were tested by ELISA. Data are expressed as the mean values of individual participants from two separate experiments; horizontal lines represent the median values of different groups. (a) Analysis of serum IL-33 levels revealed no obvious differences among different stage IgAN patients and healthy controls (HC) (all p > 0.05). No significant difference in the levels of serum IL-33 was found among each stage of IgAN patients. (b) Serum sST2 levels were significantly higher in each stage of IgAN patients than in HC and furthermore tended to increase in parallel with the severity of the histopathological classification of IgAN (r = 0.443, p < 0.001).

Mentions: Serum levels of IL-33 and sST2 were tested in 74 patients and 34 age- and sex-matched healthy individuals. Analysis of serum cytokines indicated no significant difference in the levels of serum IL-33 between patients with IgAN at each stage compared to the HC (all p > 0.05, Figure 1(a)). There was no significant difference in the concentrations of serum IL-33 between the different stages of IgAN in patients (data not shown), while the levels of serum sST2 were higher in each stage of IgAN patients than in HC (all p < 0.05, Figure 1(b)). Furthermore, the serum sST2 tended to increase in parallel with the severity of the histopathological classification of IgAN (r = 0.443, p < 0.001, Figure 1(b)).


Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy
Analysis of sera IL-33 and sST2 in IgAN patients and HC. The levels of sera sST2 and IL-33 in IgAN patients and HCs were tested by ELISA. Data are expressed as the mean values of individual participants from two separate experiments; horizontal lines represent the median values of different groups. (a) Analysis of serum IL-33 levels revealed no obvious differences among different stage IgAN patients and healthy controls (HC) (all p > 0.05). No significant difference in the levels of serum IL-33 was found among each stage of IgAN patients. (b) Serum sST2 levels were significantly higher in each stage of IgAN patients than in HC and furthermore tended to increase in parallel with the severity of the histopathological classification of IgAN (r = 0.443, p < 0.001).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC5120178&req=5

fig1: Analysis of sera IL-33 and sST2 in IgAN patients and HC. The levels of sera sST2 and IL-33 in IgAN patients and HCs were tested by ELISA. Data are expressed as the mean values of individual participants from two separate experiments; horizontal lines represent the median values of different groups. (a) Analysis of serum IL-33 levels revealed no obvious differences among different stage IgAN patients and healthy controls (HC) (all p > 0.05). No significant difference in the levels of serum IL-33 was found among each stage of IgAN patients. (b) Serum sST2 levels were significantly higher in each stage of IgAN patients than in HC and furthermore tended to increase in parallel with the severity of the histopathological classification of IgAN (r = 0.443, p < 0.001).
Mentions: Serum levels of IL-33 and sST2 were tested in 74 patients and 34 age- and sex-matched healthy individuals. Analysis of serum cytokines indicated no significant difference in the levels of serum IL-33 between patients with IgAN at each stage compared to the HC (all p > 0.05, Figure 1(a)). There was no significant difference in the concentrations of serum IL-33 between the different stages of IgAN in patients (data not shown), while the levels of serum sST2 were higher in each stage of IgAN patients than in HC (all p < 0.05, Figure 1(b)). Furthermore, the serum sST2 tended to increase in parallel with the severity of the histopathological classification of IgAN (r = 0.443, p < 0.001, Figure 1(b)).

View Article: PubMed Central - PubMed

ABSTRACT

Background. The IL-33/ST2 axis is involved in humoral immune responses. Method. The concentrations of sera IL-33 and sST2 in 74 patients and 34 healthy controls (HC) were measured by ELISA. Clinical and laboratory data were examined. The potential association between sera IL-33 and sST2 and the clinical parameters in IgAN patients were analyzed. Results. No difference was discovered in IL-33 concentrations between IgAN patients and HCs; however, the sST2 were significantly higher in each stage of IgAN progression than in the HC. The concentration of sST2 was positively correlated with IL-33 levels in IgAN patients. Higher levels of sera IL-2, IL-4, IL-10, IL-17A, and IFN-&gamma; were detected in patients compared to the HC. The concentration of serum sST2 was positively correlated with the levels of IL-10 in IgAN patients. Furthermore, serum sST2 was negatively correlated with the values of eGFR and serum calcium. Serum sST2 was positively correlated with 24-hour urinary protein, serum phosphorus, and serum IgA; however, serum IL-33 was not associated with these. Following treatment, serum sST2 was significantly decreased, while sera IL-4 and IL-10 were significantly increased. Conclusions. Increased sST2 and IL-10 but not IL-33 may be involved in the pathogenic process of IgAN.

No MeSH data available.